Robert F. Williamson is currently involved in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers.  He is on the boards of Pharmasset, Inc. (NASDAQ: VRUS) and Progen Pharmaceuticals (NASDAQ: PGLA). Previously, he was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology - which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc. - which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT).  Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc., and his clients included top global pharmaceutical and medical device companies with additional clients in high technology and energy.  Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, D.C.  He received a B.A. in Economics from Pomona College and an M.B.A. from Stanford Graduate School of Business.